Scotiabank maintains Gilead Sciences at Sector Outperform, raises price target to $200 from $177

What happened

Scotiabank maintained Gilead Sciences at Sector Outperform and raised its price target to $200 from $177, a 13.0% increase. The new target implies 17.2% upside from the Oct 30 close of $170.68.

Confirmed

Global impact / market context

A higher price target signals that this analyst expects Gilead's shares to be worth more over time, which can draw investor attention and support demand for the stock. For a beginner, a price target is an analyst's estimate of where a stock may trade.

Analyst inference

Other recent analyst targets on Gilead range from $131 to $190 across five notes, so Scotiabank's $200 sits above that group. This gap suggests mixed views on the company's prospects, with some analysts less optimistic about future returns.

Analyst inference

What to watch

1. Scotiabank's $200 target is above the $131 to $190 range from the five most recent analyst notes over the past 30 days. Confirmed
2. The article includes no company guidance, earnings dates, or drug pipeline updates, so readers should look for such disclosures when available. Proposed
3. Watch whether other analysts raise their targets toward $200; wider agreement could strengthen confidence in Gilead's outlook and support the shares. Analyst inference

Evidence

• Original source link unavailable